Thomas Stanton
Hematology & Oncology · Petaluma, CANPI 1699855445
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $5,003 of the $6,585 with a category attached, or 76.0%. Bristol Myers Squibb accounts for 64.3% of it on its own, with 23 other manufacturers making up the rest.
Across 57 payments — averaging $115.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Bristol Myers Squibb$4K
- Ipsen Biopharmaceuticals, Inc$1K
- AstraZeneca$148
- E.r. Squibb & Sons, L.L.C.$110
- Merck$69
- Bayer$68
- plus $514 from 18 others
Across 250 payments — averaging $2541.97 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- EMD Serono, Inc.$187K
- AstraZeneca$125K
- Clovis Oncology, Inc.$103K
- Roche Products Limited$76K
- Pfizer$70K
- GSK$18K
- plus $56K from 5 others
What the payments were for
- Consulting fees$5,00376%
- Travel & lodging$5118%
- Food & beverage$1,07216%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Bristol Myers Squibb | 6 | $4,236 |
| Ipsen Biopharmaceuticals, Inc | 2 | $1,440 |
| AstraZeneca(2 entities) | 8 | $148 |
| E.r. Squibb & Sons, L.L.C. | 6 | $110 |
| Merck | 4 | $69 |
| Bayer | 3 | $68 |
| Genentech USA, Inc. | 3 | $67 |
| Seagen Inc. | 3 | $55 |
| Rigel Pharmaceuticals, Inc. | 2 | $47 |
| Amgen | 2 | $40 |
| Novartis | 2 | $39 |
| Agios Pharmaceuticals, Inc. | 2 | $38 |
| Lilly USA, LLC | 2 | $36 |
| Eisai Inc. | 1 | $24 |
| Taiho Oncology, Inc. | 1 | $21 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $20 |
| Jazz Pharmaceuticals Inc. | 1 | $19 |
| AbbVie | 1 | $18 |
| Karyopharm Therapeutics Inc. | 1 | $17 |
| Astellas Pharma US Inc | 1 | $16 |
| Clovis Oncology, Inc. | 2 | $15 |
| Dendreon Pharmaceuticals LLC | 1 | $15 |
| GSK | 1 | $14 |
| Boehringer Ingelheim | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Reblozyl$4,104
- ONIVYDE$1,080
- SOMATULINE DEPOT$360
How this compares
$6,585 in reported general payments places this provider in the 60th percentile of 1,363 hematology & oncology providers in California.
Other hematology & oncology in Petaluma
- Dennis SlamonLos Angeles$3.1M
- Sandra HorningStanford$2.5M
- Mohammadbagher ZiariCorona$2.5M
- George YaghmourLos Angeles$1.9M
- Robert VescioWest Hollywood$1.1M
- Kevin KellyLos Angeles$894K
- Johnny ChangEncino$884K
- Nitin RohatgiSacramento$814K
- Omid HamidSanta Monica$809K
- Catherine CoombsOrange$786K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Identity: NPPES NPI Registry, July 2026.